Context Therapeutics Inc (CNTX)
2.16
-0.01
(-0.46%)
USD |
NASDAQ |
Jun 21, 16:00
2.17
+0.01
(+0.46%)
After-Hours: 20:00
Context Therapeutics Research and Development Expense (Quarterly): 1.973M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.973M |
| December 31, 2023 | 5.302M |
| September 30, 2023 | 4.485M |
| June 30, 2023 | 3.461M |
| March 31, 2023 | 4.535M |
| December 31, 2022 | 2.145M |
| September 30, 2022 | 2.078M |
| June 30, 2022 | 1.517M |
| March 31, 2022 | 1.352M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.294M |
| September 30, 2021 | 0.7396M |
| June 30, 2021 | 1.333M |
| March 31, 2021 | 0.4387M |
| December 31, 2020 | 0.5948M |
| September 30, 2020 | 0.4687M |
| June 30, 2020 | 0.3662M |
| March 31, 2020 | 0.2118M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.2118M
Minimum
Mar 2020
5.302M
Maximum
Dec 2023
1.900M
Average
1.352M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Emergent BioSolutions Inc | 15.10M |
| AbbVie Inc | 1.939B |
| Revance Therapeutics Inc | 14.39M |
| Design Therapeutics Inc | 9.801M |
| NovaBay Pharmaceuticals Inc | 0.019M |